Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

Condition:   Breast Tumors Intervention:   Drug: DS-8201a Sponsors:   UNICANCER;   Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 16 December 2019, highlighting Roche data presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, from 10th - 14th December.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
This study identified correlates of good screening performance for three common cancers, while weighing them against the backdrop of existing knowledge, to enable policy makers and healthcare providers focus appropriately to close the gaps that exist in cancer screening in our locale. Study design: Cross-sectional design. Setting: Tertiary health facility. Participants: Workers at Delta State University Teaching Hospital, Nigeria. Results: Females had significantly better knowledge of cervical cancer, p
Source: Ghana Medical Journal - Category: African Health Tags: Ghana Med J Source Type: research
T, Saarto T Abstract Background: To avoid aggressive treatments at the end-of-life and to provide palliative care (PC), physicians need to terminate futile anti-cancer treatments and define the palliative goal of the treatment in time. This single center study assesses the practices used to make the decision that leads to treatment with a palliative goal, i.e., the PC decision and its effect on anti-cancer treatments at the end of life.Material and methods: Patients with a cancer diagnosis treated in tertiary hospital during 1st January 2013 - 31st December 2014 and deceased by the end of 2014 were identified in t...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
This article presents recent data informing these contemporary developments in the radiotherapeutic management of breast cancer. PMID: 31739937 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Hematol Oncol Clin North Am Source Type: research
We examined multiple phenotypes with male and female homozygous Fry conditional knockout mice (Mfry) and control mice (WT), including body weight, preliminary observations (health and neurological flexes), open field locomotion, sensory abilities, auditory threshold, and glucose metabolism. The loss of Fry in the mammary glands didn't cause a significant difference in these genotypes between Mfry and WT mice. However, our data showed that Fry was required during pregnancy, while it was functionally dispensable in virgin mammary gland development. Loss of Fry led to more lateral buds, and the lobuloalveoli were smaller and ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
British Journal of Cancer, Published online: 21 November 2019; doi:10.1038/s41416-019-0636-xStudy of the antitumour effects and the modulation of immune response by histamine in breast cancer
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsDual-labeled trastuzumab showed specific accumulation in orthotopic HER2-positive BT474 breast tumors with micro-SPECT/CT and fluorescence imaging and enabled image-guided tumor resection. In the clinical setting, [111In]In-DTPA-trastuzumab-IRDye800CW could be valuable for preoperative detection of (metastatic) tumors by SPECT/CT imaging, and intraoperative localization by using a gamma probe and fluorescence image-guided surgery to improve radical resection of tumor tissue in patients with HER2-positive tumors.
Source: EJNMMI Research - Category: Radiology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
As the Puget Sound region's biotech industry continues to grow, Seattle Genetics is leading the pack with its therapeutic for lymphoma on the market and two more late-stage products for bladder and breast cancer on the way. “Seattle Genetics has reached a transformational point in its history,” CEO Clay Siegall told the Business Journal. “Seattle Genetics will remain focused on making a meaningful difference in cancer patients’ lives through discovering, developing and commercializing transformative…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news
Analyst, 2019, Advance Article DOI: 10.1039/C9AN01653H, PaperYu Zhou, Huiying Xu, Hua Wang, Bang-Ce Ye A hairpin-like aptasensor combining the specific MUC1 aptamer with a hemin/G-quadruplex is developed for the detection of breast cancer exosomes. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Research | Study